RLFTF - Relief NRx agree to settle litigation over COVID-19 therapy aviptadil

• Relief Therapeutics ( OTCQB:RLFTF ) ( OTCQB:RLFTY ) and NRx Pharmaceuticals ( NASDAQ: NRXP ) said they have agreed to a tentative settlement of their pending litigation.
• The companies have been embroiled in litigation over experimental COVID-19 therapy Zyesami (aviptadil).
• The companies noted in an Aug. 22 press release that any settlement may result in a re-allocation of the development rights and licensing arrangements for aviptadil.
• The parties have agreed to work together to finalize the settlement within the next 30 days and stay the litigation for an additional 60 days to allow for the negotiation and execution of the definitive settlement agreement.
• There can be no assurance that the parties will successfully complete the proposed settlement.
• However, the companies added that there can be no assurance that the parties will successfully complete the proposed settlement.
• In April, Relief said it entered into a stipulation to stay the proceedings in its pending litigation with NRx's unit NeuroRx, and Jonathan Javitt to allow the parties to attempt to seek to mediate their dispute.
• NRXP -1.61% to $0.70 premarket Aug. 22

For further details see: